Analytical Solutions, Inc. changes name to Tergus Pharma

In response to company growth and expansion of topical pharmaceutical product development services, Analytical Solutions, Inc. (ASI) is pleased to announce today that it is changing its name to Tergus Pharma, LLC, to better echo the company's new growth trajectory.



Tergus Co-Founder and CEO, Dr. Vijendra Nalamothu, most recently Head of Dermatology R&D for Promius Pharma and Dr. Reddy's Laboratories, brings 18 years of topical drug product development and commercialization experience to Tergus clients. Since 1994, Tergus Co-Founder and President, Dr. Kailas Thakker, has been providing quality analytical services to the pharmaceutical industry with an emphasis on In Vitro Release Testing (IVRT), functional testing for semisolids and topical products.

Tergus (Latin for "skin") is now providing dermatology drug development services from concept to commercialization.  With the acquisition of new equipment and strategic additions to the scientific team, Tergus Pharma is pleased to announce that it is now servicing its clients with a broader range of topical drug development services, including product development strategy & design; target product profile development; formulation development; analytical method development & validation; preclinical & clinical supplies manufacturing; program management & logistics leadership; scale-up & technology transfer oversight; regulatory CMC consulting; disease model development; clinical development strategy; and development plan creation to ensure fastest path to in vivo or clinical proof of concept studies.

Tergus' core expertise will remain focused in topical dosage forms, including creams, ointments, lotions, liquids, suspensions, gels, hydrogels, pastes, pump sprays, topical aerosols, foams, microencapsulation, liposomes, suppositories and nail lacquers.